Osherov Michael, Milo Ron
a Department of Neurology, Barzilai University Medical Center, Ashkelon, Faculty of Health Sciences , Ben-Gurion University of the Negev , Ashkelon , Israel.
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1037-1047. doi: 10.1080/17512433.2017.1366854. Epub 2017 Aug 22.
The goal of the article is to review the mechanism of action and the use of daclizumab, a humanized monoclonal antibody (mAb) against the alpha subunit of the high affinity interleukin-2 (IL-2) receptor, in the treatment of Multiple Sclerosis (MS). Areas covered: PubMed was searched for the terms 'daclizumab' and 'multiple sclerosis'. The mechanisms of action, pharmacokinetics and pharmacodynamics, major studies, side effects and drug interactions of daclizumab in MS are discussed. Expert commentary: Monthly daclizumab-beta [DAC-beta, formerly daclizumab high yield process (DAC HYP), approved as ZINBRYTA®, which has a different form and structure than an earlier form of daclizumab], is an effective and convenient treatment option for patients with relapsing forms of MS who have failed other treatment, or as a first-line option in highly active MS patients. IL-2 signaling modulation by daclizumab constitutes a novel mechanism of action which may also underlie the adverse and serious adverse events and risk profile of the drug that requires appropriate patient selection, monitoring and risk-mitigation programs.
本文的目的是综述抗人白细胞介素-2（IL-2）高亲和力受体α亚基的人源化单克隆抗体（mAb）达克珠单抗在治疗多发性硬化症（MS）中的作用机制及应用。涵盖领域：在PubMed上检索了“达克珠单抗”和“多发性硬化症”等术语。讨论了达克珠单抗在MS中的作用机制、药代动力学和药效学、主要研究、副作用及药物相互作用。专家评论：每月一次的达克珠单抗-β[DAC-β，以前称为达克珠单抗高产工艺（DAC HYP），获批商品名为ZINBRYTA®，其形式和结构与早期形式的达克珠单抗不同]，对于其他治疗无效的复发型MS患者，或作为高度活跃MS患者的一线治疗选择，是一种有效且方便的治疗方案。达克珠单抗对IL-2信号的调节构成了一种新的作用机制，这也可能是该药物不良事件和严重不良事件以及风险特征的基础，这就需要进行适当的患者选择、监测和风险缓解计划。
